Σύγκριση 18F-FDG και 68Ga-DOTATATE PET/CT σε νευροενδοκρινείς όγκους του ήπατος

Abstract

Purpose This paper indicates the necessity of diagnosing neuroendocrine tumors, located in the liver, with the imaging system PET/CT and with the help of radiopharmaceuticals 18F-FDG and 68Ga-DOTATATE. Also, it is aimed at reporting the functions of these two radiopharmaceuticals in the body of the patient and in the final differences between them. Materials and Μethods A total of 19 patients were included in the study and underwent both 18F-FDG and 68Ga- DOTATATE PET/CT at the Biomedical Research Foundation of the Academy of Athens (BRFAA). The principle of the procedure was the acquisition of PET/CT images in tests not exceeding 2 or 3 months and also the comparison of images of Ki67 index with the volume grade. Results The results of PET images of radiopharmaceuticals 18F-FDG and 68Ga-DOTATATE and their differences in absorption in liver tissues are presented. The values of SUVmax indicate the huge difference in the absorption of radiopharmaceutical 68Ga-DOTATATE. From the ki67 index values, the volume grades were sorted. Of the 19 patients, 3 have a G1 tumor grade, 9 have a G2 grade and 1 G3 patient. There was high absorption in tumor detection from 68Ga-DOTATATE with 30.8%, from the two radiopharmaceuticals together with a value of 46.1% and no absorption with only the radiopharmaceutical 18FFDG. Conclusions The paper showed the enormous usefulness of radiopharmaceutical 68Ga DOTATATE in neuroendocrine liver tumors which in the expression of well differentiated tumors with potentially benign behavior (G1) and well differentiated tumors with uncertain behavior (G2). On the contrary the usefulness of 18F-FDG for poorly differentiated a neuroendocrine carcinoma with a high degree of malignant behavior. There was a significant difference between the two radiopharmaceuticals and SUVmax values.